Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 219-225

  Esposito, Maria ^a   Mazzotta, A ^a   Saraceno, R ^a   Schipani, C ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Body Mass Index (BMI); Etanercept; Psoriasis; Tumor Necrosis Factor (TNF )

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GASTRITIS; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SKIN INFECTION; TREATMENT DURATION; WEIGHT GAIN;

EID: 62649136592     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200124     Document Type: Article

References (15)

1. Hamminga EA, Van der Lely AJ, Neumann HAM, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Medical Hypotheses 2006; 67:768-773.
2. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-19.
3. Hotamisligil GS, Amer P, Caro JF, Atkinson RL, Spielgman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-15.
4. Gottlieb AB, Matheson RT, Lowe N, et at. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-32.
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
6. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152(6):1304-12.
7. Eckel RH, Grundy SM, Zimmet Pz. The metabolic syndrome. Lancet 2005; 365:1415-28.
8. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366:1059-62.
9. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
10. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas Br J Nutr 1991; 65:105-14.
11. Schottelius AJG, Moldawer LL, Dinarello, CA, et al. Biology of tumor necrosis factor-α - implications for psoriasis. Exp Dermatol 2004; 13:193-222.
12. Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kB/Re1A in normal and psoriatic epidermis and downregulation of NF-kB in response to treatment with etanercept. J Invest Dermatol 2005; 124:1275-83.
13. De Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-14.
14. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22(3):341-4.
15. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-6.